Multiple studies have indicated that continuous sorafenib treatment induces tumor hypoxia, leading to the selection of tumor clones that adapt to a hypoxic environment by activating HIF-1α and NF-κB, thereby diminishing the efficacy of sorafenib (10). This evidence concerns the gene HIF1A and neoplasm.